Newleos Therapeutics Announces Clinical Advisory Board to Support Key Neuropsychiatry Programs April 29, 2025
Rectify Pharma to Share Preclinical Data Highlighting Progress in Hepatobiliary Program at EASL 2025 April 25, 2025
Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria April 15, 2025
Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic Malignancies April 9, 2025
Rectify Pharma Announces Publication of BSEP Transporter Biophysical Characterization in Communications Biology April 8, 2025
Newleos Therapeutics Expands Leadership Team to Advance its Clinical-Stage Neuropsychiatric Programs and Drive Corporate Growth April 8, 2025
